Shares are trading at $19.95 which is marginally over $18.02, the stock’s 50 day moving average and which is a tad under the 200 day moving average of $23.21. The 50 day moving average was up $1.93 whereas the 200 day average was down by -14.06%. 452K shares changed hands in the last trading session. Trading volume was down 67.79% under the stocks average daily volume.
Investors are a little more bearish on shares of the company as inferred by the motion in short interest. The company realized a rise in short interest of 9.66% as of May 31, 2017 from the last reporting period. Short shares grew 790,869 over that timeframe. Days to cover increased from 5.8 to 8.3 and the percentage of shorted shares is 0.26% as of May 31.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has been the object of insider selling activity recently. Julie Krop, SVP Clinical & Regulatory, CMO let go of $46,235 worth of shares at an average price of $24.45 on May 1st. The SVP Clinical & Regulatory, CMO now owns $899,198 of the stock as reported to the SEC. Julie Krop, SVP Clinical & Regulatory, CMO disclosed the sale of 4,938 shares of (AMAG). The shares were purchased at an average price of $24.80. Krop now owns $586,966 of the stock according to the SEC filing.
These funds have also shifted positions in (AMAG). As of quarter end Creative Planning had sold 13,495 shares trimming its holdings by 97.1%. The value in dollars went from $313,000 to $7,000 decreasing 97.8% quarter to quarter. As of the end of the quarter Bank Of Montreal /can/ had acquired a total of 10,067 shares growing its stake by 8,531.4%. The value of the investment in AMAG Pharmaceuticals, Inc. increased from $3,000 to $187,000 a change of $184,000 quarter over quarter.
As of quarter end Capstone Asset Management Co had sold 510 shares trimming its position 3.9%. The value of the investment in AMAG decreased from $293,000 to $230,000 a change of 21.5% for the reporting period. As of the end of the quarter Livforsakringsbolaget Skandia, Omsesidigt had disposed of a total of 44,912 shares trimming its holdings by 90.5%. The value of the total investment in AMAG Pharmaceuticals, Inc. decreased from $1,118,000 to $86,000 a change of 92.3% since the last quarter.
Needham added AMAG to its research portfolio giving it an initial rating of “Buy”. On May 4 the company was rated “Market Perform” by Raymond James which was a cut from the previous “Outperform” rating.
On January 28, 2016 Northland Securities starting coverage on AMAG setting a rating of “Outperform”. Equity analyst Barclays began coverage by announcing an initial rating of “Equal-weight” and a price target of $32.00.
January 14 investment analysts at Deutsche Bank left the company rating at “Hold” and lowered the price target to $42.00 from $43.00. On November 19 Deutsche Bank left the stock rating at “Hold” but moved down the price target from $50.00 to $43.00.
The company is trading up since yesterday’s close of $19.7. In the latest earnings report the EPS was $-0.92 and is expected to be $5.40 for the current year with 35,045,000 shares now outstanding. Next quarter’s EPS is forecasted to be $1.21 and the next full year EPS is projected to be $2.16.
AMAG Pharmaceuticals, Inc., launched on November 9, 1981, is a pharmaceutical company. The Business’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Company has a portfolio of products and services with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is involved in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women..Advertisement